Psyence Biomedical Ltd. announced a delay in its 1-for-6.25 reverse stock split, pushing the effective date from January 20, 2026, to February 2, 2026, causing shares to drop 5.05%. This consolidation aims to enhance market performance and investor confidence, amid concerns about company strategy.